ESR1 and breast cancer: Adjuvant tamoxifen treatment of ER positive breast cancer patients was associated with significantly lower recurrence rate in patients with an ER pathway active primary tumor, compared to patients with an ER-inactive tumor (Verhaegh et al., 2014).